ReviewMediterranean journal of rheumatology2025
Sexual Dysfunction in Systemic Autoimmune Rheumatic Diseases: Prevalence, Impact, and Management Strategies.
Review in Mediterranean journal of rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The emerging role of histone acetylation in rheumatic diseases: unraveling mechanisms and therapeutic prospects.Frontiers in immunology · 2026Review
- Pregnancy Outcomes in Autoimmune Rheumatic Diseases: A Persistent Clinical Challenge.Mediterranean journal of rheumatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Systemic autoimmune rheumatic diseases (SARDs) profoundly impact patients' quality of life (QoL) including sexual health, yet sexual dysfunction (SD) remains underrecognised in clinical care. Contributing factors include chronic pain, fatigue, joint stiffness, hormonal imbalances and psychological distress. Objective: This review evaluates the prevalence, impact, and management of SD in patients with systemic autoimmune rheumatic diseases (SARDs), including Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), Sjögren's disease (SjD), and Systemic Sclerosis (SSc), as well as the related chronic condition Fibromyalgia Syndrome (FMS). Methods: A systematic literature review was conducted using PubMed, Web of Science, and Scopus with relevant MeSH terms. Studies reporting SD in SARDs were included, with sexual function commonly assessed via the Female Sexual Function Index (FSFI) and International Index of Erectile Function (IIEF). Results: SD prevalence ranged from 30% to 90%, varying by disease and gender. Up to 90% of women with SLE reported reduced desire and arousal. RA affected 30-70% of patients, with pain and depression as key drivers. In AS, erectile dysfunction affected 41-58% of men, influenced by age and disease duration. Over 56% of women with SjD experienced SD, often linked to vaginal dryness. SSc-induced fibrosis led to erectile dysfunction in 80% of men. FMS showed a 63% SD rate, associated with chronic pain and psychological burden. Conclusion: SD is highly prevalent yet underaddressed in SARDs. A multidisciplinary approach combining pain management, psychological support, hormonal therapy, and patient education is essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.